Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

ONCY

Oncolytics Biotech, Inc

Oct 29 • 04:00PM ET

1.17

-0.05 -4.10 %

Healthcare • Biotechnology • Canada • NASD

Peers: CRSP NTLA EDIT BLUE CLLS FATE IOVA ADAP PSTX TCRT

Index	-	P/E	-	EPS (ttm)	-0.27	Insider Own	2.27%	Shs Outstand	100.36M	Perf Week	-0.85%
Market Cap	118.46M	Forward P/E	-	EPS next Y	-0.24	Insider Trans	0.00%	Shs Float	98.09M	Perf Month	-16.43%
Enterprise Value	108.39M	PEG	-	EPS next Q	-0.06	Inst Own	9.57%	Short Float	3.27%	Perf Quarter	14.71%
Income	-21.84M	P/S	-	EPS this Y	22.95%	Inst Trans	0.04%	Short Ratio	3.10	Perf Half Y	104.98%
Sales	0.00M	P/B	25.54	EPS next Y	-11.16%	ROA	-114.75%	Short Interest	3.21M	Perf YTD	28.04%
Book/sh	0.05	P/C	11.05	EPS next 5Y	11.97%	ROE	-244.84%	52W High	1.51 -22.52%	Perf Year	-4.10%
Cash/sh	0.11	P/FCF	-	EPS past 3/5Y	8.27% 23.13%	ROIC	-445.81%	52W Low	0.33 259.12%	Perf 3Y	-7.87%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	6.62% 6.00%	Perf 5Y	-48.00%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	5.09%	Oper. Margin	-	ATR (14)	0.08	Perf 10Y	-71.22%
Dividend Ex-Date	-	Quick Ratio	2.88	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	44.34	Recom	1.33
Dividend Gr. 3/5Y	- -	Current Ratio	2.88	EPS Q/Q	29.70%	SMA20	-4.76%	Beta	1.31	Target Price	4.45
Payout	-	Debt/Eq	0.15	Sales Q/Q	-	SMA50	-4.07%	Rel Volume	0.72	Prev Close	1.22
Employees	28	LT Debt/Eq	0.10	Earnings	Aug 08 BMO	SMA200	39.21%	Avg Volume	1.03M	Price	1.17
IPO	Oct 05, 2001	Option/Short	No / Yes	EPS/Sales Surpr.	30.08% -	Trades		Volume	747,632	Change	-4.10%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-13-25	Initiated	Lake Street	Buy	$7
Oct-06-22	Initiated	Maxim Group	Buy	$3
Feb-17-21	Initiated	H.C. Wainwright	Buy	$15

Oct-28-25 07:30AM	Oncolytics Biotech Reports Updated Anal Cancer Data Showing Objective Response Rate More Than Double the Current Standard of Care (PR Newswire)
Oct-20-25 09:00AM	Oncolytics Biotech Files Circular/Prospectus for Special Meeting of Shareholders To Change Jurisdiction of Incorporation to Nevada (PR Newswire)
Sep-29-25 08:30AM	Oncolytics Biotech Announces Update for Potential First-Line Pancreatic Cancer Registration Study (PR Newswire) +9.30%
Sep-16-25 12:29PM	Cancer Immunotherapy Surge Drives $258B Market as FDA Accelerates Approvals (PR Newswire)
07:00AM	Oncolytics Biotech Provides Update on GOBLET Study Progress and U.S. Site Expansion (PR Newswire)
09:30AM	Loading…
Sep-08-25 09:30AM	Breakthrough Therapy Designations Surge as $50B Cancer Drug Partnerships Reshape Market (PR Newswire) +20.75%
07:00AM	Oncolytics Biotech Highlights Strong Efficacy and Translational Data in Metastatic Colorectal Cancer; Will Advance Regulatory Pathway Discussions (PR Newswire)
Sep-02-25 09:30AM	Breakthrough Cancer Therapies Fuel Regulatory Momentum as Global Market Expands (PR Newswire) +10.58%
09:10AM	Oncolytics Biotech Provides Updated Clinical Safety Data for Pelareorep, Including Across Multiple Gastrointestinal Tumors (PR Newswire)
Aug-31-25 08:40AM	Large-cap biotech is a sector to watch for investors: Analysts (Yahoo Finance)
Aug-28-25 10:44AM	FDA Tightens Survival Standards as Cancer Drug Pipeline Hits $866B Market Milestone (PR Newswire)
08:30AM	Oncolytics Biotech Announces Upcoming Investor Conferences in September (PR Newswire)
Aug-14-25 12:30PM	Biotech Stocks Rally as Oncology Market Targets $866B by 2034 (PR Newswire) -7.81%
12:22PM	Cancer Treatment Stocks Surge as $866B Market Attracts Private Investment (PR Newswire)
Aug-11-25 04:55PM	Oncolytics Biotech Announces Voting Results from the Annual General Meeting of Shareholders (PR Newswire)
09:05AM	Loading…
Aug-08-25 09:05AM	Oncolytics Biotech Reports Second Quarter Financial Results and Details Clinical Program Plans for Pelareorep (PR Newswire) -6.20%
09:00AM	Oncolytics Biotech Announces Voluntary Delisting from the Toronto Stock Exchange (PR Newswire)
Aug-05-25 08:30AM	Oncolytics Biotech Announces Upcoming Annual General Meeting and Second Quarter Financial Results (PR Newswire) +7.58%
Jul-29-25 03:46PM	Biotech Underdogs Line Up for Pivotal Shots at Game-Changing Cancer Treatments (PR Newswire) -6.42%
08:30AM	Oncolytics Biotech to Engage FDA for Potential Registration-Enabled Study in First-Line Pancreatic Cancer with Goal to Launch Trial Activities by Year-End (PR Newswire)
Jul-23-25 09:39AM	Key Opinion Leader Event Highlights Pelareorep's Compelling Pancreatic and Gastrointestinal Data And Future Potential (PR Newswire)
09:26AM	High-Growth Oncology Market Projected For US$900bn in Revenue Despite Policy Headwinds (PR Newswire)
Jul-22-25 03:32PM	Oncolytics Biotech Regains Compliance with Nasdaq Trading Rules (PR Newswire)
Jul-16-25 06:51PM	Cancer Pipeline Milestones Coming Fast as Regulators Revisit Research Priorities (PR Newswire) +10.62% +5.60%
08:30AM	Oncolytics Biotech Presents Aggregated Translational Data Providing Evidence of Pelareorep's Effectiveness Across Multiple Tumor Types (PR Newswire)
Jul-10-25 09:20AM	Cancer Innovation Accelerates as Funding Cuts Loom and Biotechs Step Up (PR Newswire) -7.08%
08:30AM	Oncolytics Biotech to Host Key Opinion Leader Discussion Focusing on Pancreatic and Gastrointestinal Cancers (PR Newswire)
Jul-08-25 08:30AM	Oncolytics Biotech Highlights Transformative Pelareorep Survival Data in Multiple Tumors and Commitment to Registration-Enabling Studies (PR Newswire) +23.76%
Jun-30-25 11:02AM	Oncology Innovation Just Hit a Turning Point -- Here's What to Watch (PR Newswire)
07:00AM	Oncolytics Biotech Appoints Former Ambrx Executive as Chief Business Officer to Drive Business Development Strategy (PR Newswire)
11:44AM	Loading…
Jun-26-25 11:44AM	The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough? (PR Newswire)
Jun-24-25 12:52PM	Wall Street Eyes Breakout Cancer Therapies Amid Soaring Drug Prices (PR Newswire) +5.79%
Jun-20-25 09:21AM	With Public Funding Under Pressure, Biotech Innovators Are Picking Up the Slack in Oncology (PR Newswire) -6.74%
Jun-18-25 11:19AM	Cancer Rates Are Surging in Young Adults -- Here's Where the Smart Money Is Going (PR Newswire) +10.76%
Jun-12-25 10:00AM	As Public Cancer Funding Wavers, Oncology's Brightest Breakthroughs Are Coming From Industry (PR Newswire)
09:00AM	After Major Oncology Conference, All Eyes Turn to Industry Innovation (PR Newswire)
Jun-11-25 07:00AM	Oncolytics Biotech Names New CEO to Accelerate Momentum in Immunotherapy Programs (PR Newswire) +34.10%
May-23-25 09:10AM	New Data and Deal Flow Signal a Turning Point for Precision-Driven Cancer Biotechs (PR Newswire)
07:00AM	Oncolytics Biotech to Present New Clinical Trial Data at ASCO Showing Pelareorep's Unique Immune Activation Capabilities (PR Newswire)
May-15-25 03:15AM	Oncolytics Biotech Inc (ONCY) Q1 2025 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com)
May-14-25 04:01PM	Oncolytics Biotech Reports First Quarter Financial Results and Highlights Clinical Momentum (PR Newswire)
May-06-25 07:00AM	Oncolytics Biotech to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights (PR Newswire) -6.42%
May-01-25 11:04AM	New Cancer Treatments Spark Hope as Traditional Funding Faces Uncertainty (PR Newswire)
Apr-24-25 07:00AM	Oncolytics Biotech to Showcase New Pancreatic Cancer Data at ASCO Highlighting Pelareorep's Tumor-Fighting Mechanism of Action (PR Newswire)
Apr-14-25 10:15AM	With Young Adult Cancer on the Rise, New Therapies Spark Investor Buzz (PR Newswire) -5.28%
Apr-10-25 06:09PM	Oncolytics Biotech Funds Pelareorep's Ongoing Clinical Development with a Share Purchase Agreement in Partnership with Alumni Capital (PR Newswire) +24.56%
07:00AM	Oncolytics Biotech and Pelareorep Discussed During Recent H.C. Wainwright Key Opinion Leader Event on Oncolytic Immunotherapies in Breast and Pancreatic Cancers (PR Newswire)
Mar-08-25 07:33AM	Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge (PR Newswire)
02:03AM	Oncolytics Biotech Inc (ONCY) Q4 2024 Earnings Call Highlights: Promising Cancer Study Results ... (GuruFocus.com)
Mar-07-25 07:00AM	Oncolytics Biotech Reports Highlights and Financial Results for Q4 and Year-End 2024 (PR Newswire) -6.29%
Mar-05-25 09:35AM	Oncolytics Biotech (ONCY) Loses -9.34% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks) +13.52%
Feb-27-25 10:10AM	Oncology Breakthroughs: How Cancer Research Is Advancing in 2025 (PR Newswire)
Feb-25-25 07:00AM	Oncolytics Biotech to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights (PR Newswire)
Feb-19-25 10:10AM	Investors Eye Biotech Sector as Cancer Therapy Market Surges (PR Newswire)
07:00AM	Oncolytics Biotech Advances Key Pancreatic and Anal Cancer Trials, Strengthening Pipeline in 2025 (PR Newswire)
Feb-18-25 07:00AM	Oncolytics Biotech® Strengthens Its Pipeline in 2025 with Key Pancreatic and Anal Cancer Advances in Addition to Metastatic Breast Cancer (PR Newswire)
Feb-14-25 05:15PM	Oncolytics Biotech Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency (PR Newswire)
Feb-07-25 09:24PM	Oncolytics Biotech Announces Matt Coffey, Ph.D. Will Not Return to CEO Role Following Medical Leave of Absence (PR Newswire)
Feb-05-25 12:00PM	Oncolytics Biotech (ONCY) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Jan-22-25 09:00AM	Oncology's Best Minds Set to Meet at Upcoming 2025 ASCO Gastrointestinal Cancers Symposium (PR Newswire) +5.26%
07:00AM	Oncolytics Biotech to Present Compelling New Efficacy and Safety Data in Anal and Pancreatic Cancers at 2025 ASCO GI Symposium (PR Newswire)
Jan-16-25 11:17AM	German PEI approves enrolment in cohort 5 of Oncolytics pancreatic cancer trial (Clinical Trials Arena)
Jan-15-25 10:10AM	Cutting-Edge Cancer Therapies Lead the Way into a Transformative Year (PR Newswire)
07:02AM	Regulatory Approval Clears Path for Oncolytics Biotech to Advance Promising Pancreatic Cancer Treatment, Following a Review of Safety Data (PR Newswire)
Dec-26-24 11:26AM	Oncology in Focus: How Emerging Therapies Are Reshaping Cancer Treatment (PR Newswire)
09:00AM	Achievements and Progress Heading into 2025 for Oncology Treatments and Therapies Fuel an Optimistic Outlook (GlobeNewswire)
Dec-23-24 10:49AM	How Cutting-Edge Immunotherapies Are Redefining Cancer Treatment Options (PR Newswire) +9.00%
07:00AM	Oncolytics Biotech Highlights 2024 Achievements and Prepares for an Influential 2025 with Promising Breast and GI Cancer Data (PR Newswire)
Dec-20-24 12:52PM	Oncology Advancements Accelerate Amid Rising Early-Onset Cancer Diagnoses (PR Newswire) -6.36%
Dec-18-24 11:12AM	Cancer Care Disruptions Highlight Growing Demand for Innovative Oncology Treatments (PR Newswire)
08:45AM	Promising Data for Treating Gastrointestinal Cancer Leading to Hopeful Advancements for Pancreatic and Anal Cancers (GlobeNewswire)
07:00AM	Oncolytics Biotech to Present Promising Pelareorep Data in Pancreatic and Anal Cancers at ASCO GI Symposium (PR Newswire)
Dec-03-24 07:00AM	Oncolytics Biotech Reports Completion of Initial Safety Phase Enrollment for GOBLET Trial's New Pancreatic Cancer Cohort (PR Newswire)
Dec-02-24 10:18AM	Biotech Advances Drive Cancer Research as Global Rates Continue Upward Trend (PR Newswire)
Nov-14-24 08:00AM	Biotech Companies' Q3 Updates: Promising Cancer Treatments on the Horizon (PR Newswire)
Nov-13-24 02:08AM	Oncolytics Biotech Inc (ONCY) Q3 2024 Earnings Call Highlights: Strategic Advances and ... (GuruFocus.com) -8.04%
Nov-12-24 07:00AM	Oncolytics Biotech Reports Third Quarter 2024 Financial Results and Operational Highlights (PR Newswire)
Nov-11-24 07:00AM	Oncolytics Biotech to Host Conference Call to Discuss Third Quarter Financial Results and Recent Operational Highlights (PR Newswire)
Oct-15-24 07:32AM	Breast Cancer Awareness Month Sees Biotech Advancements and Worrying Trends for Young Women (PR Newswire) +7.83%
Oct-07-24 11:21AM	Oncolytics targets accelerated approval for oncolytic virus therapy (Pharmaceutical Technology) +27.27%
Oct-04-24 09:00AM	FDA Approves 16 New Cancer Treatments as Global Cancer Rates Skyrocket (PR Newswire) +18.22%
07:00AM	Oncolytics Biotech Announces Key Progress and Upcoming Studies for Breast and Pancreatic Cancer Treatments, Prepares for FDA Accelerated Approval Path (PR Newswire)
Sep-24-24 09:15AM	Optimism Grows in the Fight Against Cancer as Breakthroughs and Funding Increase (PR Newswire)
Sep-20-24 11:08AM	Global Cancer Rates Surge as Biotech Innovators Work on New Therapies (PR Newswire)
09:00AM	How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for Biotechs (GlobeNewswire)
Sep-19-24 12:08PM	Cancer Research Sees Major Boost as New Breakthroughs Emerge from Key Oncology Players (PR Newswire)
07:00AM	Oncolytics Biotech Reports Favorable Results for BRACELET-1 Breast Cancer Study Reinforcing Path to Funding of a Registration-Enabling Study (PR Newswire)
Sep-06-24 08:00AM	Oncolytics Biotech to Participate in Fireside Chats at Two Investment Conferences in September (PR Newswire)
Aug-12-24 04:37PM	Biotech Innovations: Revolutionary Treatments Aim to Boost Pancreatic Cancer Survival Rates (PR Newswire)
07:45AM	Sernova Corp. Announces Appointment of New Chief Executive Officer (GlobeNewswire)
Aug-02-24 07:00AM	Oncolytics Biotech to Participate in a Fireside Chat at Canaccord Genuity's 44th Annual Growth Conference (PR Newswire)
Aug-01-24 04:01PM	Oncolytics Biotech Reports Second Quarter 2024 Financial Results and Operational Highlights (PR Newswire)
Jul-24-24 07:00AM	Oncolytics Biotech to Host Conference Call to Discuss Second Quarter Financial Results and Recent Operational Highlights (PR Newswire)
Jun-27-24 03:28PM	American Cancer Society Projects Over 2 Million New Cases in 2024: Biotech Innovations Respond (PR Newswire)
07:00AM	Oncolytics Biotech Announces Productive FDA Type C Meeting on its Metastatic Breast Cancer Program (PR Newswire)
Jun-24-24 07:00AM	Oncolytics Biotech Announces President and Chief Executive Officer Dr. Matt Coffey to Take Medical Leave of Absence (PR Newswire)
Jun-21-24 06:53AM	Oncolytics doses first subject in pancreatic cancer trial (Clinical Trials Arena)
Jun-20-24 05:26PM	Biotech Advances Propel Oncology Market to $564.5B Amid Youth Cancer Spike (PR Newswire)
10:00AM	Pancreatic Cancer Market Is Projecting to Expand As NCI-Funded Research Expects to Empower Market Growth (GlobeNewswire)
08:45AM	Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7.5 Billion by 2033 (GlobeNewswire)

Oncolytics Biotech, Inc. engages in the provision of development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. It offers a non-pathogenic, properietary isolation of the reovirus that induces selective tumor lysis and promotes an inflamed tumor phenotype through innate and adaptive immune responses. The company was founded by Matthew C. Coffey and Bradley George Thompson on April 2, 1998 and is headquartered in Calgary, Canada.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ONCY

Oncolytics Biotech, Inc

Upgrade your FINVIZ experience